SCHEMBL1483566

SCHEMBL1483566

CC(=O)c1ccc(N2CCN(C(C)=O)CC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.71
ALDH1A1 P00352 7/20 0.71
KMT2A Q03164 4/20 0.71
CASP6 P55212 1/20 0.69
GFER P55789 1/20 0.69
MEN1 O00255 2/20 0.65
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
CYP2C9 P11712 1/20 0.60
HPGD P15428 1/20 0.60
CYP2C19 P33261 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.58
POLB P06746 1/20 0.58
KDM4E B2RXH2 1/20 0.58
LMNA P02545 1/20 0.58
MAPK1 P28482 3/20 0.57
TP53 P04637 2/20 0.57
USP2 O75604 1/20 0.57
HSD17B10 Q99714 1/20 0.57
THRB P10828 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17669252 0.90 MAPT (0.71) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL15801114 0.90 MAPT (0.71) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL3028108 0.87 MAPT (0.69) MAPTALDH1A1KMT2ACASP6GFER
SCHEMBL14802425 0.87 GFER (0.67) MAPTALDH1A1KMT2ACASP6GFER
SCHEMBL4985313 0.86 GFER (0.70) MAPTALDH1A1KMT2ACASP6GFER
SCHEMBL10876210 0.86 GFER (0.65) MAPTALDH1A1KMT2ACASP6GFER
SCHEMBL1484133 0.86 MAPT (0.67) MAPTALDH1A1KMT2ACASP6GFER
SCHEMBL1372140 0.85 MAPT (0.66) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL27845814 0.84 MAPT (0.65) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL336009 0.83 NPC1 (0.65) MAPTALDH1A1KMT2AGFERMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391667-B2 N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-08-19 US disclosed
EP-4003978-B1 N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2024-05-01 EP disclosed
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-20220281838-A1 N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THETREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-09-08 US disclosed
US-20220281838-A1 N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THETREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-09-08 US disclosed
WO-2021013833-A1 N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-01-28 WO disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed
US-20170058031-A1 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF SQUIBB & SONS LLC (US) 2017-03-02 US disclosed
US-20170058031-A1 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF SQUIBB & SONS LLC (US) 2017-03-02 US disclosed
US-9499632-B2 Human antibodies that bind CD22 and uses thereof E.R. SQUIBB & SONS, L.L.C. (US) 2016-11-22 US disclosed
US-20090162372-A1 FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE MEDAREX, INC. (US) 2009-06-25 US disclosed
US-20090162372-A1 FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE MEDAREX, INC. (US) 2009-06-25 US disclosed
WO-2009073533-A2 ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE MEDAREX, INC. (US) 2009-06-11 WO disclosed
WO-2009073524-A2 CONJUGATES OF ANTI-RG-1 ANTIBODIES MEDAREX, INC. (US) 2009-06-11 WO disclosed
WO-2009073546-A2 MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) MEDAREX, INC. (US) 2009-06-11 WO disclosed
EP-2049508-A2 N-HYDROXY-3-(4-{3-PHENYL-3-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER DAC S.r.l. (IT) 2009-04-22 EP disclosed
WO-2009026274-A1 SITE-SPECIFIC ATTACHMENT OF DRUGS OR OTHER AGENTS TO ENGINEERED ANTIBODIES WITH C-TERMINAL EXTENSIONS MEDAREX, INC. (US) 2009-02-26 WO disclosed
WO-2007113249-A2 N-HYDROXY-3-(4-{3-PHENYL-S-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER DAC S.R.L. (IT) 2007-10-11 WO disclosed
US-20060247228-A1 Phenylazole compounds production process and antioxidants NIPPON SODA CO., LTD. (JP) 2006-11-02 US disclosed
EP-1650206-A1 PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS, AND ANTIOXIDANTS NIPPON SODA CO., LTD. (JP) 2006-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162372-A1 FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE FN1, EDNRB, EDF1 MAPT 3372/4885ALDH1A1 4183/4885KMT2A 3018/4885
US-20220281838-A1 N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THETREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES ENPP2, MYT1, INMT MAPT 1693/4885ALDH1A1 3517/4885KMT2A 539/4885
US-20170058031-A1 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF CD2BP2, CD22, CD2 MAPT 3906/4885ALDH1A1 1167/4885KMT2A 1158/4885
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 MAPT 442/4885ALDH1A1 4188/4885KMT2A 3168/4885
US-20060247228-A1 Phenylazole compounds production process and antioxidants CBR1, CBR3, NOX3 MAPT 2754/4885ALDH1A1 232/4885KMT2A 4566/4885
US-12391667-B2 N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases ENPP2, MYT1, INMT MAPT 1681/4885ALDH1A1 3760/4885KMT2A 552/4885
US-11666661-B2 Methods and compounds for targeted autophagy ATG7, BECN1, SQSTM1 MAPT 442/4885ALDH1A1 4188/4885KMT2A 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.